The hypothesis that treatment when only a lower burden of tumor is present is attractive because the TME ratio of CD8 T cells to ST2+ Treg cells, and to MLL-AF9 cells, will be favorable for antigen-specific WT1+CD8+ T cells to be able to kill the leukemia. The gene discussed is KMT2A; the disease is neoplasm.